Posted by admin on Aug 15th, 2022

Paragon 28 (NYSE:FNA – Get Rating) is one of 216 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its rivals? We will compare Paragon 28 to similar businesses based on the strength of its profitability, institutional ownership, dividends, valuation, earnings, analyst recommendations and risk.

This is a breakdown of recent ratings and target prices for Paragon 28 and its rivals, as provided by MarketBeat.

Paragon 28 presently has a consensus target price of $26.17, suggesting a potential upside of 34.33%. As a group, “Surgical & medical instruments” companies have a potential upside of 28.20%. Given Paragon 28’s stronger consensus rating and higher possible upside, analysts plainly believe Paragon 28 is more favorable than its rivals.

This table compares Paragon 28 and its rivals’ net margins, return on equity and return on assets.

12.3% of Paragon 28 shares are owned by institutional investors. Comparatively, 51.0% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 19.5% of Paragon 28 shares are owned by insiders. Comparatively, 14.7% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

This table compares Paragon 28 and its rivals top-line revenue, earnings per share and valuation.

Paragon 28’s rivals have higher revenue and earnings than Paragon 28. Paragon 28 is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Paragon 28 beats its rivals on 8 of the 12 factors compared.

Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; and APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides bunion or hallux valgus correction systems, including nail systems phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

Receive News & Ratings for Paragon 28 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paragon 28 and related companies with MarketBeat.com's FREE daily email newsletter.

Hammerson plc (LON:HMSO) Receives Average Rating of “Reduce” from Analysts

Legrand SA (OTCMKTS:LGRDY) Given Consensus Recommendation of “Hold” by Brokerages